In men with advanced prostate cancer, survival after therapy with a luteinizing hormone–releasing hormone (LHRH) agonist was
found to be equivalent to survival after orchiectomy. Although patients prefer to avoid orchiectomy, it is unknown whether
this procedure decreases quality of life. No evidence shows a difference in effectiveness or adverse effects among the LHRH
agonists.